Application of moringa oleifera leaf extract in preparation of fat-reducing medicine or functional food
By preparing and applying Moringa leaf extract, the problem of insufficient research on fat-reducing function in existing technologies has been solved, resulting in a significant reduction in body weight and fat cell volume in mice, providing a safe and economical fat-reducing drug and functional food solution.
Patent Information
- Application Number
- CN202511279297.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-09
- Publication Date
- 2025-12-02
AI Technical Summary
In the current technology, the fat-reducing function of Moringa leaf extract has not been fully studied and applied, especially in terms of reducing fat cell volume and improving local fat accumulation, and it cannot effectively address the problem of obesity.
Moringa leaf extract was prepared by using efficient extraction methods such as soaking in 95% ethanol and vacuum concentration to prepare low-dose and high-dose Moringa leaf extracts. These extracts were then used in a high-fat, high-cholesterol diet-induced obese mouse model to observe their effects on mouse body weight, subcutaneous fat, and abdominal white adipose tissue.
Moringa leaf extract significantly slowed weight gain in mice and significantly reduced the weight of abdominal white adipose tissue and subcutaneous fat. The high-dose group showed better results than the positive control drug rosiglitazone, demonstrating excellent fat-reducing efficacy. It is safe, has few side effects, is inexpensive, and is suitable for long-term use.
Smart Images
Figure CN121041331A_ABST
Abstract
Description
Technical Field
[0001] This application relates to the field of pharmaceutical technology, and in particular to the application of a Moringa leaf extract in the preparation of weight-loss drugs or functional foods. Background Technology
[0002] Against the backdrop of sustained global economic growth and a general improvement in living standards, dietary imbalances and lifestyle changes have led to an increasingly prominent obesity problem. The "World Obesity Report 2024" indicates that the number of obese people worldwide has exceeded one billion, with China becoming one of the countries with the largest obese population. Obesity not only impairs an individual's quality of life but is also closely related to the occurrence of various chronic diseases such as cardiovascular disease and diabetes, posing a serious challenge to public health.
[0003] With rising obesity rates and increased health awareness, the weight loss product market is expanding rapidly. Consumers' demands for weight loss products have gradually shifted from simply focusing on weight loss effects to a comprehensive consideration of safety, user experience, and convenience. In 2023, the Chinese weight loss market reached 411.4 billion yuan, with an annual growth rate of 8.29%. Against this backdrop, the research and development of fat-reducing products has ushered in new development opportunities. Unlike "lipid reduction," which mainly targets blood lipid control, "fat reduction" focuses more on reducing the size and number of fat cells, optimizing body composition, and fat distribution. Moringa leaf extract, as a natural active substance, has received widespread attention due to its potential fat-reducing function.
[0004] Moringa leaf extract is rich in various nutrients and antioxidants, possessing multiple biological activities such as lowering blood sugar, regulating blood lipids, promoting excretion, and diuresis, which are beneficial for weight control. Studies have confirmed that this extract can effectively inhibit the activity of key enzymes in carbohydrate and lipid metabolism, α-glucosidase and pancreatic lipase, thereby exerting its hypoglycemic and lipid-lowering effects. Furthermore, it can enhance glucose uptake by 3T3-L1 preadipocytes and regulate lipid metabolism-related indicators, providing theoretical support for its application in lipid management. However, the potential of Moringa leaf extract in fat reduction, especially its function in reducing adipocyte volume and improving localized fat accumulation, has not yet been fully studied and applied, which is an important direction for addressing obesity. Summary of the Invention
[0005] In view of this, this application provides an application of Moringa leaf extract in the preparation of fat-reducing drugs or functional foods. The Moringa leaf extract can promote fat metabolism and decomposition, reduce fat cell volume, and exhibit excellent fat-reducing effects. It can effectively improve the symptoms of obese mice induced by a high-fat, high-cholesterol diet, specifically by reducing mouse weight, subcutaneous fat, and abdominal white fat, and can effectively overcome the defects of the prior art.
[0006] The first aspect of this application provides the use of Moringa leaf extract in the preparation of weight-loss drugs or functional foods, comprising the following steps:
[0007] S1. After feeding mice under constant temperature and humidity conditions for one week, the mice were divided into 5 groups according to their weight, with 8 mice in each group. The 5 groups were: normal control Con group, high fat and high cholesterol HFC model group, low dose Moringa leaf extract L-MOL intervention group, high dose Moringa leaf extract H-MOL intervention group, and positive drug rosiglitazone RSG intervention group.
[0008] S2. Except for the normal control group Con, all other groups were given a high-fat diet and administered the drug by gavage at 10:00 am every day. The weight of the mice was observed and recorded for 60 consecutive days.
[0009] S3. After stopping the drug for 24 hours after step S2, the mice were anesthetized and blood was collected. They were then euthanized by cervical dislocation and dissected. The abdomen of the mice was dissected and photographed to observe the fat accumulation. The weight of subcutaneous fat and abdominal white fat of each group of mice was recorded.
[0010] Preferably, in step S1, the mice are 40 8-week-old male C57BL / 6J mice of the specific pathogen-free SPF grade, weighing 18-20 g.
[0011] Preferably, in step S1, the preparation process of the Moringa leaf extract is as follows: first, Moringa leaves are air-dried and pulverized into powder; then, the powder is soaked in 95% ethanol for 7 days, filtered three times, and the filtrate is collected; finally, the filtrate is concentrated under vacuum at 45°C until there is no ethanol odor, and then dried to obtain the Moringa leaf extract.
[0012] Preferably, in step S1, the dosage of the low-dose Moringa leaf extract L-MOL intervention group is 200 mg / kg, the dosage of the high-dose Moringa leaf extract H-MOL intervention group is 400 mg / kg, and the dosage of the positive control drug rosiglitazone RSG intervention group is 10 mg / kg.
[0013] Preferably, in step S2, the high-fat feed comprises the following components by weight percentage: 60% fat, 1.2% cholesterol, 38.8% carbohydrates and protein.
[0014] A second aspect of this application also provides a weight-loss drug, wherein the weight-loss drug uses the above-mentioned Moringa leaf extract as its active ingredient.
[0015] A third aspect of this application also provides a weight-loss functional food, which includes the aforementioned Moringa leaf extract.
[0016] Compared with the prior art, this application has the following advantages:
[0017] 1. The Moringa leaf extract of this application can significantly slow down the weight gain of mice, and its high-dose group is even better than the positive drug group; it can also significantly reduce the weight of abdominal white fat, and the difference is very obvious; it can also significantly reduce the weight of subcutaneous fat in mice, and the difference is very significant compared with the positive drug group.
[0018] 2. This application provides a food-medicine homologous extract that is naturally derived, highly safe, and has few side effects. The Moringa leaf extract in this application focuses on fat reduction, which is significantly different from lipid-lowering effects. Furthermore, Moringa leaves are a new resource food, and its extract has few toxic side effects, is inexpensive, convenient to take, and can be used for a long time. It is expected to become a relatively safe and reliable fat-reducing drug that can be taken for a long time to improve obesity. Attached Figure Description
[0019] To more clearly illustrate the technical solutions in this application or the prior art, the drawings used in the description of this application or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of this application. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.
[0020] Figure 1 Line graphs showing the changes in body weight in each group of mouse models in this application;
[0021] Figure 2 A statistical graph showing the abdominal white fat weight data of mice in each group after 8 weeks of administration in this application;
[0022] Figure 3 A statistical graph showing the subcutaneous fat weight data of mice in each group after 8 weeks of administration in this application;
[0023] Figure 4 The images show the abdominal openings of mice in each group after 8 weeks of administration. Detailed Implementation
[0024] To make the objectives, technical solutions, and advantages of this application clearer, the technical solutions of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of this application, not all embodiments. Based on the embodiments of this application, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this application.
[0025] Unless otherwise specified, the experimental methods used in the embodiments of this application are all conventional methods.
[0026] In the following examples and comparative examples, unless otherwise specified, all raw materials can be prepared by commercial purchase or conventional methods.
[0027] Example 1: Preparation of Moringa Leaf Extract
[0028] The preparation of Moringa leaf extract includes the following steps:
[0029] S1. Weigh out 2 kg of dried Moringa leaves;
[0030] S2. Grind the Moringa leaves from step S1 into a fine powder using a grinder.
[0031] S3. Place the moringa leaf powder obtained in step S2 into a 10L container;
[0032] S4. Add sufficient 95% ethanol to the container in step S3 to ensure that the powder is completely covered by ethanol.
[0033] S5. Seal the container and soak it in a constant temperature environment for seven days;
[0034] S6. After soaking for seven days, use a 2L vacuum filter to filter the solution and remove undissolved solid residue.
[0035] S7. To improve extraction efficiency, the S6 step is repeated three times, with each time the filtrate is replaced with fresh 95% ethanol to ensure that as many active ingredients as possible are extracted.
[0036] S8. Combine the filtrates obtained from the three filtrations.
[0037] S9. Using a vacuum concentration device, concentrate the filtrate obtained in step S8 at 45°C. This temperature can reduce the loss of heat-sensitive components.
[0038] After concentrating in steps S10 and S9 until there is no alcohol odor, turn off the equipment and allow the extract to cool naturally to room temperature.
[0039] S11. The extract cooled in step S10 is dried using a vacuum dryer.
[0040] S12. Weigh the Moringa leaf extract obtained in step S11 to obtain 380 g of Moringa leaf extract, and store it under dry, light-proof and cool conditions to maintain its stability and efficacy.
[0041] Example 2: Lipid-reducing effect of Moringa leaf extract in obese mice induced by a high-fat, high-cholesterol diet.
[0042] This embodiment uses the Moringa leaf extract from Example 1 as the test subject and implements a high-fat, high-cholesterol diet-induced obese mouse experiment to verify the fat-reducing effect of Moringa leaf extract on obese mice.
[0043] 1. Experimental Method:
[0044] (1) Mouse grouping:
[0045] Forty 8-week-old male C57BL / 6J mice, weighing 18-20 g and of specific pathogen-free SPF grade, were selected. After one week of feeding under constant temperature and humidity (temperature controlled at 18-22℃, humidity at 50-60%), they were randomly divided into 5 groups (n=8 per group) according to their weight: normal control (Con group), high-fat, high-cholesterol HFC model group, low-dose Moringa leaf extract L-MOL intervention group (200 mg / kg), high-dose Moringa leaf extract H-MOL intervention group (400 mg / kg), and positive control drug rosiglitazone (RSG) intervention group (10 mg / kg).
[0046] It should be noted that the groups were respectively designated as the control group, the high-fat and high-cholesterol group, Moringa leaf (200 mg / kg), Moringa leaf (400 mg / kg), and Rosiglitazone (10 mg / kg).
[0047] (2) Prepare a low-dose intervention drug from Moringa leaves:
[0048] Using a precision balance of 0.01 g / day, 60 mg of Moringa leaf extract was accurately weighed into a 5 mL ethylene oxide sterile (EP) tube. Using a high-precision pipette, 3 mL of ultrapure water was added to the EP tube. The Moringa leaf extract was then completely dissolved by gentle vortexing and sonication to prepare a low-dose solution of 20 mg / mL.
[0049] (3) Prepare high-dose intervention drugs from Moringa leaves:
[0050] 120 mg of Moringa leaf extract was accurately weighed into a 5 mL ethylene oxide sterile (EP) tube using a 0.01 g / day precision balance. 3 mL of ultrapure water was added to the EP tube using a high-precision pipette. The Moringa leaf extract was completely dissolved by gentle vortexing and ultrasonic mixing, thus preparing a high-dose solution of 40 mg / mL.
[0051] (4) Preparation of positive control drug:
[0052] Weigh 4 mg of rosiglitazone into a 5 mL ethylene oxide (EP) sterile tube using a balance with an accuracy of 1 / 100,000. Add 2‰ dimethyl sulfoxide (DMSO), 5% Tween 80, and physiological saline to the EP tube using a high-precision pipette. Then, gently vortex the solution in the EP tube to ensure complete dissolution of the rosiglitazone. This prepares a precise 1 mg / mL rosiglitazone solution.
[0053] (5) Administration to mice:
[0054] Mice in the normal control group (Con group) were fed a normal diet (purchased from Guangdong Provincial Experimental Animal Center). The other groups were fed a high-fat diet (HFC, 60% fat, 1.2% cholesterol, 38.8% carbohydrates and protein, purchased from ResearchDiet, USA). The three intervention groups set up in (1) – the low-dose Moringa leaf extract L-MOL intervention group, the high-dose Moringa leaf extract H-MOL intervention group, and the positive drug rosiglitazone RSG intervention group – were administered the solutions prepared in (2) to (4) by gavage. The drugs were administered at 10:00 am every day, and the weight of the mice was observed and recorded. The administration was carried out by gavage for 60 consecutive days.
[0055] (6) After stopping the medication for 24 hours after step (5), blood was collected under anesthesia, the patient was euthanized by cervical dislocation and dissected, and abdominal anatomical diagrams and fat weights were recorded for each group.
[0056] 2. Experimental Results:
[0057] The results are shown in the figure. Figure 1 It is evident that Moringa leaf extract can effectively inhibit weight gain induced by a long-term HFC diet in mice. During the 60-day administration period of Moringa leaf extract, compared with the high-fat, high-cholesterol group, the weight gain trend of the Moringa leaf extract intervention group was significantly slowed down, and the effect was enhanced in a dose-dependent manner. Furthermore, the high-dose Moringa leaf extract intervention group was even more effective than the positive control drug rosiglitazone intervention group, indicating that Moringa leaf extract can have a significant fat-reducing effect on obese mice.
[0058] Depend on Figure 2 It is evident that the abdominal fat weight of the high-fat, high-cholesterol group was significantly increased compared with the control group (p < 0.001). Compared with the high-fat, high-cholesterol group, the abdominal white fat of the Moringa leaf (200 mg / kg) group was reduced. Compared with the high-fat, high-cholesterol group, the abdominal white fat of the Moringa leaf (200 mg / kg) group and the positive control drug (rosiglitazone (10 mg / kg)) group was also reduced (P < 0.001). These results indicate that Moringa leaf extract can achieve a fat-reducing effect by reducing abdominal white fat, and the effect increases in a dose-dependent manner.
[0059] It should be noted that, Figure 2 In comparison, the high-fat, high-cholesterol group and the control group... This indicates that p < 0.05. This indicates that p < 0.01. # indicates p < 0.001; compared with the high-fat, high-cholesterol group, # indicates p < 0.05, ## indicates p < 0.01, and ### indicates p < 0.001.
[0060] Depend on Figure 3It is evident that the subcutaneous fat weight of mice in the high-fat, high-cholesterol group was significantly higher than that in other groups, and the increase in subcutaneous fat weight compared with the control group was extremely significant (p < 0.001), indicating successful model establishment. Compared with the high-fat, high-cholesterol group, the subcutaneous fat weight of the Moringa leaf (200 mg / kg) intervention group was reduced by 45.8%, a highly significant difference (p < 0.01); compared with the high-fat, high-cholesterol group, the subcutaneous fat weight of the Moringa leaf (400 mg / kg) intervention group was reduced by 58.3%, an extremely significant difference (p < 0.001); compared with the high-fat, high-cholesterol group, the subcutaneous fat weight of the positive control group (rosiglitazone (10 mg / kg)) intervention group was reduced by 66.7%, an extremely significant difference (p < 0.001). These data indicate that Moringa leaf extract can significantly reduce subcutaneous fat weight in obese mice induced by a high-fat, high-cholesterol diet, and this reduction is dose-dependent, with the high-dose intervention group showing effects close to those of the positive control group.
[0061] It should be noted that, Figure 3 In comparison, the high-fat, high-cholesterol group and the control group... This indicates that p < 0.05. This indicates that p < 0.01. # indicates p < 0.001; compared with the high-fat, high-cholesterol group, # indicates p < 0.05, ## indicates p < 0.01, and ### indicates p < 0.001.
[0062] Depend on Figure 4 As can be seen from the abdominal anatomical diagram, the volume and number of white adipose tissue in the high-fat, high-cholesterol abdomen were significantly increased. The abdominal adipose tissue in the treated mice was significantly reduced, with the Moringa leaf (400 mg / kg) group showing a significantly greater reduction than the Moringa leaf (200 mg / kg) group. The adipocytes were smaller, and the adipose tissue structure was more compact. These results indicate that Moringa leaf extract can effectively reduce abdominal fat accumulation and achieve a fat-reducing effect.
[0063] Example 3
[0064] This embodiment provides a functional food containing Moringa leaf extract: the Moringa leaf extract is prepared and extracted according to food-grade processes. It can be used alone as a functional food, or in combination with other functional foods such as plant-based Chinese herbal medicines, fruits and vegetables, tea and plant spices, fried foods, and animal-based meat, bones, eggs, dairy products, and marine organisms; or applied to foods such as grains, fruits and vegetables, beverages, and protein products, but its daily dosage should be controlled within 50-200mg. Therefore, weight loss can be achieved through the consumption of functional foods.
[0065] Example 4
[0066] This embodiment provides the use and main applications of a medicine containing Moringa leaf extract: Medicines containing Moringa leaf extract can be used alone or in combination with other similar medicines under the guidance of a physician; combined use can effectively reduce fat. Moringa leaf extract can be used in combination with suitable pharmaceutical excipients, such as excipients, carriers, diluents, and stabilizers, to prepare different dosage forms of pharmaceutical preparations according to conventional methods, such as tablets, capsules, granules, fine granules, powders, oral liquid preparations, injections, suspensions, emulsions, solutions, syrups, and pills. Different dosage forms of pharmaceutical preparations can be administered orally or non-orally. That is, the appropriate method of administration, dosage, and frequency of administration can be selected according to age, weight, and the patient's symptoms. However, for general adults, the daily oral dose of Moringa leaf extract is usually 600 mg, divided into two doses.
[0067] In conclusion, mouse experiments effectively demonstrate that Moringa leaf extract has a significant fat-reducing effect on obesity in mice, and that Moringa leaf extract itself has a higher safety profile.
[0068] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of this application, and are not intended to limit them. Although this application has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of this application.
Claims
1. The application of Moringa leaf extract in the preparation of weight-loss drugs or functional foods, characterized in that, Includes the following steps: S1. After feeding mice under constant temperature and humidity conditions for one week, the mice were divided into 5 groups according to their weight, with 8 mice in each group. The 5 groups were: normal control Con group, high fat and high cholesterol HFC model group, low dose Moringa leaf extract L-MOL intervention group, high dose Moringa leaf extract H-MOL intervention group, and positive drug rosiglitazone RSG intervention group. S2. Except for the normal control group Con, all other groups were given a high-fat diet and administered the drug by gavage at 10:00 am every day. The weight of the mice was observed and recorded for 60 consecutive days. S3. After stopping the drug for 24 hours after step S2, the mice were anesthetized and blood was collected. They were then euthanized by cervical dislocation and dissected. The abdomen of the mice was dissected and photographed to observe the fat accumulation. The weight of subcutaneous fat and abdominal white fat of each group of mice was recorded.
2. The application of the Moringa leaf extract according to claim 1 in the preparation of weight-loss drugs or functional foods, characterized in that, In step S1, the mice used are 40 8-week-old male C57BL / 6J mice of specific pathogen-free SPF grade, weighing 18-20 g.
3. The application of the Moringa leaf extract according to claim 1 in the preparation of weight-loss drugs or functional foods, characterized in that, In step S1, the preparation process of the Moringa leaf extract is as follows: first, Moringa leaves are air-dried and pulverized into powder; then, the powder is soaked in 95% ethanol for 7 days, filtered three times, and the filtrate is collected; finally, the filtrate is concentrated under vacuum at 45°C until there is no ethanol odor and then dried to obtain Moringa leaf extract.
4. The application of the Moringa leaf extract according to claim 1 in the preparation of weight-loss drugs or functional foods, characterized in that, In step S1, the dosage of the low-dose Moringa leaf extract L-MOL intervention group was 200 mg / kg, the dosage of the high-dose Moringa leaf extract H-MOL intervention group was 400 mg / kg, and the dosage of the positive control drug rosiglitazone RSG intervention group was 10 mg / kg.
5. The application of the Moringa leaf extract according to claim 1 in the preparation of weight-loss drugs or functional foods, characterized in that, In step S2, the high-fat feed comprises the following components by weight percentage: 60% fat, 1.2% cholesterol, 38.8% carbohydrates and protein.
6. A weight-loss drug, characterized in that, The weight-loss drug uses the Moringa leaf extract as described in claim 1 as its active ingredient.
7. A weight-loss functional food, characterized in that, The weight-loss functional food includes the Moringa leaf extract as described in claim 1.